通过向并发症和减少心房的负担来改变心房的管理:第十届AFNET/EHRA共识会议
Emma Svennberg1, Jose Luis Merino2, Jason Andrade3
1Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
概括
心房动 (AF) 管理正在向个性化,多领域治疗发展. 专家建议将中风预防,节律控制和条件治疗结合起来,以获得更好的患者结果.
科学领域:
- 心脏病学 心脏病学
- 医学创新 医学创新
- 卫生政策 卫生政策
背景情况:
- 心房动 (AF) 是一个显著且日益增长的未满足的医疗需求.
- 目前的治疗重点是预防中风,管理并存疾病和节律控制.
- 创新包括新的抗血栓性药物,抗心律失常药物 (AAD) 和干预疗法.
研究的目的:
- 概述关于心房动多领域治疗的新兴共识.
- 描述个性化风险估计和治疗选择方面的进展.
- 强调需要在AF管理中采用综合方法.
主要方法:
- 共识会议涉及80多名来自学术界和工业界的专家.
- 讨论中风预防,节律控制和心脏代谢疗法的创新.
- 探索AF表型和风险驱动治疗的定量特征.
主要成果:
- 新兴的共识有利于综合性多领域治疗,包括中风预防,节律控制和并发症管理.
- 个性化AF风险估计正在取代简单的得分,利用可量化的特征.
- 组合疗法 (抗凝剂,ADS,切除,心脏代谢药物) 旨在降低AF风险和并发症.
结论:
- 建议转向基于AF表型的以风险为导向的个性化治疗.
- 数据科学和人工智能可以提高风险估计和治疗选择.
- 综合,以患者为中心的AF管理需要持续研究扭转AF驱动因素并改善中风预防.
相关概念视频
Rheumatic Heart Disease III: Medical Management
264
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
264
Heart Failure V: Medical Management
198
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
198
Dysrhythmias VI: Management of Dysrhythmias
411
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
411
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Mitral Stenosis III: Medical Management
220
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
220


